Clinical Trials Directory

Trials / Completed

CompletedNCT01310335

Effect of Whole-Body Vibration on Plasma Sclerostin Level

Effect of Whole-Body Vibration on Plasma Sclerostin Level in Healthy Young Adult Women

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
15 (actual)
Sponsor
Bagcilar Training and Research Hospital · Other Government
Sex
Female
Age
20 Years – 40 Years
Healthy volunteers
Accepted

Summary

The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women. Fifteen healthy young adult women are planned to include in this study. All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period. Training duration will be short at the beginning but progressed slowly. The amplitude of vibration will be 2 mm and the frequency of the vibration will be 40 Hz. The subjects will be asked to report negative side effects or adverse reactions in their training diary. Previbration and postvibration (just after, 10.minute and 30.minute) levels of plasma sclerostin will be measured on first, second and fifth day of experiment. Sclerostin levels will be measured by human sclerostin ELISA kit.

Detailed description

Whole-body vibration has a strong osteogenic effect. The cyclic mechanical loading to the bone stimulates the osteocytes. Sclerostin, the protein product of the SOST gene, is an osteocyte-specific cysteine knot-secreted glycoprotein that is a potent inhibitor of bone formation. Sost/sclerostin levels have been reported to be reduced by mechanical stimulation. The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women.

Conditions

Interventions

TypeNameDescription
DEVICEwhole-body vibration (WBV)All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.

Timeline

Start date
2011-04-01
Primary completion
2011-04-01
Completion
2011-04-01
First posted
2011-03-08
Last updated
2016-02-25

Locations

1 site across 1 country: Turkey (Türkiye)

Source: ClinicalTrials.gov record NCT01310335. Inclusion in this directory is not an endorsement.